QNTM

MKT CAP:$15M

Quantum BioPharma Ltd.

Market Cap

$15M

Healthcare·Drug Manufacturers - Specialty & Generic·🇨🇦 Canada·NASDAQ

Healthcare·Drug·🇨🇦·NASDAQ

Stock Price

$3.44-$3.57 (-50.93%)

Apr 21, 2026

Company Details

Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders ...

CEO

Lakshmi Kotra

IPO Date

Jun 8, 2018

Website

www.quantumbiopharma.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$25M

EPS (Diluted)

-$36.79

Free Cash Flow

-$15M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 8, 2026

PENDING

FY 2025

Dec 30, 2025

$0EPS -$8.11

Q4 2025

Dec 30, 2025

$0EPS -$0.79

Q2 2023

Jun 30, 2023

$0EPS -$9.10

Q1 2023

Mar 31, 2023

$0EPS -$16.61

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 17	$0	$0	$0
Q3 17	$0	$0	$0
Q4 17	$0	$0	$0
Q1 18	$22.6K	$22.6K	-$2M
Q4 18	$572	$572	-$4M
Q4 19	$116.3K	-$734.6K	-$6M
Q1 20	$0	$0	-$5M
Q2 20	$0	$0	-$5M
Q4 20	$0	$0	-$6M
Q4 21	$0	$0	-$6M
Q2 22	$0	$0	-$8M
Q3 22	$0	$0	-$7M
Q4 22	$0	$0	-$7M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$9M
Q4 25	$0	-$131.4K	-$2M

Valuation

Quarter	P/S	P/E
Q2 17	—	—
Q3 17	—	—
Q4 17	—	—
Q1 18	3952.3x	—
Q4 18	11550.9x	—
Q4 19	287.6x	—
Q1 20	204.4x	—
Q2 20	305.8x	—
Q4 20	278.7x	—
Q4 21	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 17	-$4.0K	-$4.0K
Q3 17	-$2.6K	-$2.6K
Q4 17	-$2.7K	-$2.7K
Q1 18	-$976.4K	-$3M
Q4 18	-$2M	-$2M
Q4 19	-$2M	-$3M
Q1 20	-$5M	-$5M
Q2 20	$0	$0
Q4 20	-$5M	-$5M
Q4 21	-$4M	-$4M
Q2 22	-$9M	-$9M
Q3 22	-$8M	-$8M
Q4 22	-$6M	-$6M
Q1 23	-$5M	-$5M
Q2 23	-$4M	-$4M
Q4 25	-$305.2K	-$305.2K

Capital Expenditures

Quarter	CapEx
Q2 17	$0
Q3 17	$0
Q4 17	$0
Q1 18	$2M
Q4 18	$161.2K
Q4 19	$333.5K
Q1 20	$0
Q2 20	$0
Q4 20	$0
Q4 21	$0
Q2 22	$5.3K
Q3 22	$96.9K
Q4 22	$1.2K
Q1 23	$0
Q2 23	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 17	—	—
Q3 17	—	—
Q4 17	—	—
Q1 18	—	—
Q4 18	—	—
Q4 19	—	—
Q1 20	—	—
Q2 20	-100.0%	+138.6%
Q4 20	-100.0%	+36.7%
Q4 21	-100.0%	-0.8%
Q2 22	—	+61.0%
Q3 22	—	+51.6%
Q4 22	—	+10.6%
Q1 23	—	+60.9%
Q2 23	—	+12.3%
Q4 25	—	-67.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 17	$0	—
Q3 17	$0	—
Q4 17	$0	—
Q1 18	$787.1K	3478.8%
Q4 18	$2M	355326.6%
Q4 19	$2M	2081.0%
Q1 20	$2M	—
Q2 20	$364.1K	—
Q4 20	$215.3K	—
Q4 21	$341.6K	—
Q2 22	$355.0K	—
Q3 22	$586.5K	—
Q4 22	$506.6K	—
Q1 23	$3M	—
Q2 23	$403.4K	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 17	—	$2.3K	—	—
Q3 17	—	$4.5K	—	—
Q4 17	—	$3.7K	—	—
Q1 18	—	$2M	$1.8K	—
Q4 18	—	$3M	$836.0K	—
Q4 19	—	$5M	—	—
Q1 20	$221.7K	$4M	—	—
Q2 20	$2M	$2M	$360.8K	—
Q4 20	$2M	$2M	$215.3K	—
Q4 21	$852.4K	$4M	—	—
Q2 22	$1M	$5M	—	—
Q3 22	$2M	$4M	$586.5K	—
Q4 22	$3M	$2M	$506.6K	—
Q1 23	$2M	$3M	$3M	—
Q2 23	$2M	$3M	—	—
Q4 25	$71.5K	—	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$29M	$0	$29M
Q2 22	$32M	$0	$32M
Q3 22	$24M	$28.8K	$24M
Q4 22	$17M	$23.2K	$17M
Q1 23	$9M	$23.2K	$9M
Q2 23	$6M	$0	$6M
Q3 23	$4M	$739.6K	$4M
Q4 23	$3M	$756.1K	$4M
Q1 24	$1M	$760.1K	$2M
Q2 24	$3M	$21.9K	$3M
Q3 24	$3M	$3M	$7M
Q4 24	$6M	$1M	$7M
Q1 25	$4M	$20.9K	$4M
Q2 25	$1M	$30.8K	$2M
Q3 25	$445.9K	$636.8K	$1M
Q4 25	$2M	$4M	$6M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 17	101K	0.0%	0.0%
Q3 17	101K	0.0%	0.0%
Q4 17	101K	0.0%	0.0%
Q1 18	101K	0.0%	0.0%
Q4 18	104K	+3.4%	+3.4%
Q4 19	112K	+7.6%	+11.3%
Q1 20	125K	+11.5%	+24.1%
Q2 20	139K	+11.1%	+37.9%
Q4 20	300K	+115.1%	+186.7%
Q4 21	576K	+92.4%	+412.6%
Q2 22	592K	+2.7%	+372.2%
Q3 22	588K	-0.7%	+322.1%
Q4 22	598K	+1.7%	+99.5%
Q1 23	599K	+0.3%	+4.0%
Q2 23	604K	+0.7%	+2.0%
Q4 25	4M	+544.1%	+561.4%

Shares Outstanding